The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Abstract CT012: PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC)2024 · 1 citations
2Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast CancerCohort Study · 2022 · 89 citations
3Abstract PO2-19-11: NOBLE – Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer2024
4Short- and long-term efficacy of olaparib combined with chemotherapy in advanced triple-negative breast cancer2025
5Abstract RF5-03: OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancerEarly-Phase Clinical Trial · 2026 · 7 citations
6Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity TrialOriginal Research · 2021 · 18 citations
7Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.2024 · 4 citations
8Neoadjuvant combination treatment of olaparib and pembrolizumab for patients with HRD-positive advanced ovarian cancer.2024 · 8 citations
9Common genetic variants influence human subcortical brain structuresNature · 2015
10In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid LoweringNature · 2026

More from Nature

More from University of Oxford